PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30740643-2 2019 Bempedoic acid (ETC-1002) is a novel low-density lipoprotein cholesterol (LDL-C)-lowering agent, currently under trial in hypercholesterolaemic patients. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 component of oligomeric golgi complex 2 Homo sapiens 74-79 30740643-2 2019 Bempedoic acid (ETC-1002) is a novel low-density lipoprotein cholesterol (LDL-C)-lowering agent, currently under trial in hypercholesterolaemic patients. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 component of oligomeric golgi complex 2 Homo sapiens 74-79 24978142-1 2014 PURPOSE OF REVIEW: To review the profile of ETC-1002, as shown in preclinical and clinical studies, including LDL-cholesterol (LDL-C)-lowering activity and beneficial effects on other cardiometabolic risk markers as they relate to the inhibition of adenosine triphosphate-citrate lyase and the activation of adenosine monophosphate-activated protein kinase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 44-52 component of oligomeric golgi complex 2 Homo sapiens 110-125 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 component of oligomeric golgi complex 2 Homo sapiens 60-95 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 component of oligomeric golgi complex 2 Homo sapiens 97-102 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 component of oligomeric golgi complex 2 Homo sapiens 60-95 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 component of oligomeric golgi complex 2 Homo sapiens 97-102 29910030-2 2018 The objective of CLEAR Tranquility (NCT03001076) was to evaluate the efficacy and safety of bempedoic acid when added to background lipid-modifying therapy in patients with a history of statin intolerance who require additional LDL-C lowering. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 92-106 component of oligomeric golgi complex 2 Homo sapiens 228-233 29910030-7 2018 Bempedoic acid added to background lipid-modifying therapy that included ezetimibe reduced LDL-C by 28.5% more than placebo (p < 0.001; -23.5% bempedoic acid, +5.0% placebo). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 component of oligomeric golgi complex 2 Homo sapiens 91-96 29910030-10 2018 CONCLUSIONS: Bempedoic acid may provide an oral therapeutic option complementary to ezetimibe in statin intolerant patients who require additional LDL-C lowering. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 13-27 component of oligomeric golgi complex 2 Homo sapiens 147-152 29609755-2 2018 Bempedoic acid (ETC-1002) is a novel once-daily LDL-C-lowering agent in phase 3 clinical trials. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 component of oligomeric golgi complex 2 Homo sapiens 48-53 29609755-2 2018 Bempedoic acid (ETC-1002) is a novel once-daily LDL-C-lowering agent in phase 3 clinical trials. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 component of oligomeric golgi complex 2 Homo sapiens 48-53 27206943-2 2016 OBJECTIVES: To compare 2 doses of ETC-1002, alone or combined with ezetimibe 10 mg (EZE), vs EZE monotherapy for lowering low-density lipoprotein cholesterol (LDL-C). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 34-42 component of oligomeric golgi complex 2 Homo sapiens 122-157 27206943-6 2016 The combination of ETC-1002, 120 mg or 180 mg plus EZE reduced LDL-C by 43% and 48%, respectively (both P < .0001 vs EZE). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 19-27 component of oligomeric golgi complex 2 Homo sapiens 63-68 24978142-1 2014 PURPOSE OF REVIEW: To review the profile of ETC-1002, as shown in preclinical and clinical studies, including LDL-cholesterol (LDL-C)-lowering activity and beneficial effects on other cardiometabolic risk markers as they relate to the inhibition of adenosine triphosphate-citrate lyase and the activation of adenosine monophosphate-activated protein kinase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 44-52 component of oligomeric golgi complex 2 Homo sapiens 127-132 34813529-0 2021 Bempedoic acid: LDL-C lowering without adverse reactions. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 component of oligomeric golgi complex 2 Homo sapiens 16-21